Market News & Trends
Quotient Sciences & Druggability Technologies Announce Collaboration
Quotient Sciences and Druggability Technologies recently announced a collaboration to utilize Quotient’s integrated Translational Pharmaceutics platform to advance the development of DRGT-46, a novel, fast-acting formulation of celecoxib using proprietary super-API compositions developed by DRGT.
Cambrex Expands Analytical Capabilities
Cambrex Corporation recently announced it is investing $1 million at its High Point, NC, site to fit out 1,300 sq ft of analytical laboratory space and plans to hire 9 chemical research and development scientists, as well as 6 analytical research and development scientists pursuant to this project.
Translate Bio Expands Patent Portfolio With Newly Issued US Patent Relating to its mRNA Therapeutics Platform
Translate Bio recently announced that the USPTO has issued US Patent No. 10,143,758, Liver Specific Delivery of Messenger RNA, which builds on the company’s 2009 patent filing…
RedHill Biopharma Announces Positive Top-Line Results From Confirmatory Phase 3 Study
RedHill Biopharma Ltd. recently announced positive top-line results from the ERADICATE Hp2 study, a two-arm, randomized, double-blind, active comparator-controlled, confirmatory Phase 3 study with TALICIA (RHB-105) for H.…
MilliporeSigma Signs Exclusive Agreement With BioDuro
MilliporeSigma has signed a supply and OEM agreement with BioDuro, LLC, on exclusive terms, for worldwide distribution of AISF ([4-(Acetylamino)phenyl]-ImidodiSulfuryl diFluoride), a convenient, shelf-stable, crystalline…
Sienna Biopharmaceuticals Announces Topical Drug Study Results
Sienna Biopharmaceuticals, Inc. recently announced top-line results from a Phase 2b study of SNA-120 (pegcantratinib), the company’s lead drug candidate developed using its proprietary Topical…
Melissa Unlocks Insight & Revenue With Breakthrough AI Tools for Clinics & Research Centers
Melissa, a leading provider of global contact data quality and identity verification solutions, recently announced advanced artificial intelligence (AI) solutions that combine machine reasoning, natural…
GSK to Acquire Oncology Focused Biopharmaceutical Company
GlaxoSmithKline plc recently announced that the companies have entered into a definitive agreement pursuant to which GSK will acquire TESARO, an oncology focused company based…
Cartridge Filling: Combination of Features That Can Help Gain a Competitive Edge
By 2050, it is projected that the proportion of people aged 65 and older will be more than double that of children aged 5. This global phenomenon is also leading to an increasing number of people suffering from chronic diseases, such as diabetes and osteoporosis.
Domain Therapeutics Signs R&D Collaboration & License Agreement With Boehringer Ingelheim
Domain Therapeutics recently announced announces a multi-target drug discovery collaboration and licensing agreement with Boehringer Ingelheim on orphan G Protein-Coupled Receptors (GPCRs) in the Central Nervous System (CNS) disease area.
Catalent Invests $14 Million to Expand Biologics Packaging Capabilities Following 20th Drug Approval
Catalent Pharma Solutions recently announced that following the site’s 20th commercial product approval, it is investing nearly $14 million to expand biologics packaging capabilities and capacity at its Bloomington, IN, biologics manufacturing facility.
Neurelis Announces Acquisition of Leading Drug Delivery Technology Company
Neurelis, Inc. recently announced the acquisition of Aegis Therapeutics, a San Diego-based drug delivery technology company.
SELLAS Life Sciences Announces Completion of Enrollment in Phase 2 Randomized Controlled Clinical Study
SELLAS Life Sciences Group, Inc. recently announced the completion of enrollment for a Phase 2 independent investigator-sponsored clinical trial of the combination of trastuzumab (Herceptin)…
Opthea Confirms Final Patient Enrolment in Phase 2b Wet AMD Clinical Trial
Opthea Limited recently announced the last patient has been enrolled in the company’s ongoing Phase 2b trial of OPT-302 for wet age-related macular degeneration (AMD),…
Novo Nordisk Announces Phase 3a Results Using Emisphere’s Technology
Novo Nordisk recently announced the completion and results regarding its Pioneer 9 and Pioneer 6 Phase 3a trials, both conducted with oral semaglutide, a once-daily…
CBT Pharmaceuticals & Zhejiang Bossan Pharmaceutical Enter Collaboration & License Agreement
CBT Pharmaceuticals (CBT) and Zhejiang Bossan Pharmaceutical Co., Ltd (Bossan) recently announced they have entered into a clinical collaboration and license agreement to develop their…
Dalton Pharma Services Enters Drug Development & Manufacturing Services Agreement
Dalton Pharma Services recently announce a drug development and manufacturing services agreement with ExCellThera Inc. This agreement provides ExCellThera access to Dalton’s state-of-the-art cGMP, Health…
Edge Therapeutics Enters Into Merger Agreement With PDS Biotechnology
Edge Therapeutics, Inc. and PDS Biotechnology Corporation recently announced their respective boards of directors have approved a definitive merger agreement. The merger is expected to…
Ajinomoto Bio-Pharma Services Introduces Bioconjugation Technology for ADC Manufacturing
Ajinomoto Bio-Pharma Services recently presented data at the World ADC Summit in San Diego this month describing a proprietary site-selective bioconjugation technology, AJICAP.
Evelo & Merck Enter Clinical Trial Collaboration
Evelo Biosciences, Inc. recently announced it has entered into a clinical trial collaboration agreement with Merck. The collaboration will evaluate EDP1503 in combination with KEYTRUDA (pembrolizumab).
